If you or a loved one is taking Tysabri, recognizing early signs of PML—such as progressive weakness, vision changes, or confusion—can be critical. The history of pharmaceutical safety has evolved from broad population-level education to a focus on individual risk, and this page outlines the symptoms to watch for and what they may mean.
Tysabri (natalizumab) is a biologic therapy approved as monotherapy for relapsing forms of multiple sclerosis and for Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus. For patients in Illinois who have developed PML after Tysabri exposure, understanding the medical evidence and legal context—including the statute of limitations for filing a claim—is critical. The prescribing information for Tysabri includes a boxed warning stating that the drug 'increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain that usually leads to death or severe disability' (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This warning is based on clinical data and postmarketing reports. Three specific risk factors have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered when initiating or continuing therapy, as they directly influence the likelihood of PML development.
PML typically presents with progressive neurological deficits, including cognitive decline, motor weakness, visual disturbances, and speech difficulties. Diagnosis relies on clinical presentation, brain MRI showing characteristic white matter lesions, and detection of JC virus DNA in cerebrospinal fluid via PCR. The condition often leads to severe disability or death, as noted in the boxed warning. The mechanistic pathway linking Tysabri to PML involves the drug's action as an alpha-4 integrin antagonist, which inhibits lymphocyte migration into the central nervous system. This immunosuppressive effect can allow latent JC virus to reactivate and cause lytic infection of oligodendrocytes, leading to demyelination and neuronal damage. The adequacy of warnings regarding Tysabri and PML has been a subject of legal scrutiny. The prescribing information includes a boxed warning and mandates enrollment in the TOUCH Prescribing Program, which requires patients to read a Medication Guide and understand the risks (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). However, some patients and their families have argued that these warnings were insufficient or that the risks were not adequately communicated before treatment began.
For Illinois residents, the statute of limitations for filing a product liability or personal injury lawsuit related to Tysabri and PML is generally two years from the date the injury was discovered or should have been discovered, as per Illinois law (735 ILCS 5/13-202). This timeline is critical because PML symptoms may not appear until months or years after Tysabri exposure, and the clock starts when the patient or their representative becomes aware of the link between the drug and the harm. Settlement considerations for affected patients often involve evaluating the severity of the injury, the duration of Tysabri treatment, and the presence of risk factors such as anti-JCV antibody status. The timeline between exposure and documented harm is a key factor: PML can develop after a few months to several years of therapy, as noted in the prescribing information for herpes infections, which shares a similar latency pattern (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). For PML specifically, the risk increases with longer treatment duration, especially beyond two years. Patients who develop PML may be eligible for compensation through settlements or litigation, but they must act within the statute of limitations. In Illinois, the discovery rule applies, meaning the statute of limitations begins when the plaintiff knows or reasonably should know that their injury was caused by Tysabri. This can be complex in PML cases because initial symptoms may mimic multiple sclerosis relapses, delaying diagnosis. Once PML is confirmed, the patient has two years to file a claim. Given the severe outcomes associated with PML, prompt legal consultation is advisable for affected individuals and their families.
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
In Illinois, the statute of limitations for filing a product liability or personal injury lawsuit related to Tysabri and PML is generally two years from the date the injury was discovered or should have been discovered, as per Illinois law (735 ILCS 5/13-202). The discovery rule applies, meaning the clock starts when the patient or their representative knows or reasonably should know that Tysabri caused the harm.
Three specific risk factors have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered when initiating or continuing therapy.
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.